Best in Biotech 12 Aug 2025 Six psychedelic drug companies aiming to revolutionize mental health treatment Psychedelic drugs have the potential to become an effective treatment for crippling mental health conditions such as depression. In this article, we take a look at six of the top… August 12, 2025 - 2 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
Best in Biotech 16 Jan 2025 Ten first-in-class drugs on track for FDA approval in 2025 …for CagriSema. Perhaps 2026 will be its year. As 2025 unfolds, the industry will watch closely to see if these first-in-class drug candidates meet their potential. For patients living with… January 16, 2025 - 13 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
News and Trends 23 May 2023 Ironwood acquires VectivBio in $1B deal …to tender their shares in the tender offer. VectivBio Headquartered in Basel, Switzerland, VectivBio is a clinical-stage biotechnology company focused on the discovery and development of treatments for severe, rare… May 23, 2023 - 5 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 20 Jul 2022 WuXi Biologics to build new center in Singapore as part of $1.4B investment …by 2026 and is anticipated to employ 1,500 research, development and manufacturing staff when complete. Following investments in the U.S., Ireland, Germany and China, this new addition in Singapore will… July 20, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 21 Dec 2021 Argenx’s Potential Blockbuster Gets FDA Nod for Autoimmune Disease …Vantage Pharma, the drug is predicted to make €2.7B ($3B) in sales by 2026. argenx has also applied for approval in the EU, which is expected in summer 2022. The… December 21, 2021 - 4 minutesmins - By Anita Chakraverty Share WhatsApp Twitter Linkedin Email
News and Trends 20 Jul 2022 ICL and PlantArcBio look to use RNAi to boost crop yields ICL, a global specialty minerals company, and ag-biotech company PlantArcBio, Ltd., have announced the development of a novel bio-stimulant technology platform to improve crop yields while having a minimal impact… July 20, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 27 Sep 2024 Aptadir Therapeutics launches to develop new class of RNA inhibitors against cancer and genetic disorders The biotech market is still going strong as more startups focused on therapeutic research crop up. Just this week, Italian startup Aptadir Therapeutics launched with $1.6 million to bring a… September 27, 2024 - 6 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
In Depth 15 May 2024 Drugs for IgA nephropathy on the rise in the clinic …as they tend to have little to no symptoms early on. That’s why it is called a silent disease, explained Renée Aguiar-Lucander, chief executive officer (CEO) of Swedish biotech Calliditas. … May 15, 2024 - 9 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 4 Nov 2019 Finnish Genetics Study Provides Clues for Treating Type 2 Diabetes …type 2 diabetes. Drugs blocking zinc transporter proteins could mimic the mutation’s effects, resulting in higher insulin levels. The US biotech Regeneron Pharmaceuticals and big pharma Pfizer partly funded and… November 4, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
In Depth 5 Nov 2025 Novo Nordisk’s pipeline plan: How the pharma giant is refocusing amid major restructuring …the end of 2026, reallocating resources toward growth opportunities in diabetes and obesity, and ending a heart failure cell therapy partnership with Heartseed before deciding to discontinue cell therapy research… November 5, 2025 - 10 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
News and Trends 18 Jan 2017 New Combo Therapy for Type 2 Diabetes to Sweep Europe …life to its blockbuster in the ever more competitive type 2 diabetes market, expected to reach €64B by 2026. Starting with Eli Lilly’s Abasaglar, a biosimilar of Lantus, and Intarcia‘s… January 18, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 16 Apr 2025 Beyond CRISPR: Brink Therapeutics raises $4 million with engineered recombinases A fresh take on gene-editing, centered on engineered recombinases, emerges as Brink Therapeutics, a Paris-based biotech startup, secures €3.5 million ($4 million) in seed funding with Kuma Partners and Breega… April 16, 2025 - 7 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email